Peptides: BPC-157 for Gut Healing
BPC-157 heals NSAID-induced and ethanol-induced gastric ulcers in rats at 10mcg/kg oral dose within 24h (PMID 21548867). Unique property: stable in stomach acid. No human IBD/GI trials completed as of 2026.
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | C | grade | Animal grade — GI evidence entirely from rat models; no completed human GI RCTs; significant evidence gap for human IBD/IBS applications |
| BPC-157 Origin | Human gastric juice | biological source | BPC-157 was originally identified as a cytoprotective peptide in human gastric secretions — gut healing was the primary research focus before other applications |
| Acid Stability | Stable in gastric acid | property | Unlike most peptides, BPC-157 resists degradation in stomach acid — this enables oral administration and is unusual for therapeutic peptides |
| Oral Dose (Rat) | 10 | mcg/kg | Standard oral dose in rat ulcer models; significant gastric healing observed at 24h in NSAID and ethanol-induced ulcer models |
| Ulcer Healing Speed | Significant at 24h | time point | Rat gastric ulcer models show significant mucosal healing at 24 hours post oral BPC-157 vs control (animal study) |
| IBD Models Studied | TNBS and DSS colitis | models | Both trinitrobenzene sulfonic acid (TNBS) and dextran sulfate sodium (DSS) colitis rat models showed improvement with BPC-157 treatment |
| Human GI Evidence | None | trials | No completed human clinical trials for BPC-157 in any GI condition as of 2026 — the human IBD gap is significant |
BPC-157’s connection to gut health is not incidental — the peptide was discovered in the gastric system, and GI healing was the original focus of the Sikiric laboratory’s research before the peptide became widely known in performance communities for tendon and systemic applications.
Origin: From Gastric Juice to Research Peptide
BPC-157 was isolated from a protein found in human gastric juice. The “BPC” nomenclature — Body Protection Compound — reflects its originally proposed cytoprotective role in the gastric mucosa. The rationale was that the stomach produces protective peptides that help the mucosa resist acid damage, and identifying and characterizing these peptides could lead to treatments for ulcer disease.
This origin story has a practical implication: BPC-157 is stable in gastric acid. This is unusual. Most therapeutic peptides are rapidly hydrolyzed by stomach acid and pepsin, making oral administration ineffective. BPC-157’s acid stability means oral dosing maintains biological activity in rat studies — a property that distinguishes it from nearly all other injectable peptides.
The Gut Evidence Base
All BPC-157 gut evidence comes from animal studies, primarily rats. The research from Sikiric and colleagues (University of Zagreb) covers multiple GI conditions:
| Gut Condition | Model | Key Finding | Dose Used | Evidence Level |
|---|---|---|---|---|
| Gastric ulcer (NSAID-induced) | Rat, indomethacin model (animal study) | Significant mucosal healing at 24h; faster ulcer closure vs control | 10mcg/kg oral | C — animal only |
| Gastric ulcer (ethanol-induced) | Rat ethanol model (animal study) | Cytoprotection; reduced mucosal damage vs control | 10mcg/kg oral/IP | C — animal only |
| Alcohol-induced gut damage | Rat systemic ethanol model (animal study) | Reduced intestinal permeability; less mucosal hemorrhage | 10mcg/kg | C — animal only |
| IBD / colitis (TNBS model) | Rat TNBS colitis (animal study) | Reduced inflammatory scores; mucosal healing; less weight loss | 10mcg/kg | C — animal only |
| IBD / colitis (DSS model) | Rat DSS colitis (animal study) | Improved colon histology; reduced cytokine markers | 10mcg/kg | C — animal only |
| Gut anastomosis healing | Rat intestinal anastomosis model (animal study) — PMID 22843063 | Improved anastomotic strength; reduced leakage; faster healing | 10mcg/kg | C — animal only |
| Human gut (IBD/IBS) | No trials conducted | No data available | — | No human evidence |
Why the Human Gap Matters More Here
For athletic tendon injuries, the human evidence gap means a motivated user is taking on personal risk to test an animal-model hypothesis. For gut conditions like IBD or Crohn’s disease, the evidence gap is more medically significant:
-
IBD is a chronic inflammatory condition with established, evidence-based treatments (biologics like infliximab, adalimumab; 5-aminosalicylates; immunomodulators). These treatments have human RCT data.
-
Self-treating IBD with an unproven peptide while not using evidence-based therapies carries genuine risk of disease progression, complications (strictures, fistulas), and missed diagnoses.
-
BPC-157 may work for gut healing in humans. It also may not work at sufficient doses or may interact with existing medications. Without human trials, these questions cannot be answered.
Oral vs. Injectable for Gut Applications
For upper GI conditions (gastric ulcer, esophagitis, small bowel):
- Oral administration has mechanistic advantages — BPC-157 contacts the mucosal surface directly, and its acid stability means it survives the journey to the affected tissue
For lower GI conditions (colitis, IBD affecting colon):
- Subcutaneous injection may provide more consistent systemic delivery, since an orally administered peptide may be partially absorbed before reaching the colon
- Some researchers have proposed enema administration for colonic delivery, but this route has no established protocol
The practical challenge: no human bioavailability data exists for any route. All route recommendations are extrapolated from rat studies.
Related Pages
Sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease. Curr Pharm Des. 2011;17(16):1612-32. PMID 21548867
- Klicek R et al. Short-term and long-term effects of BPC 157 on healing of damaged intestinal anastomosis. Inflamm Res. 2012;61(11):1165-75. PMID 22843063
- Sikiric P et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2018;24(18):1990-2001. PMID 29663863
Frequently Asked Questions
Why is BPC-157's stability in stomach acid significant?
Most therapeutic peptides are destroyed in the stomach by acid and proteases, making oral delivery impractical. BPC-157 is an exception — rat studies demonstrate it maintains biological activity after oral administration. This matters because it means oral dosing is a plausible route, particularly for gut-targeted applications where a compound that survives stomach acid and encounters the intestinal lining directly may be more effective than an injected systemic dose.
Is BPC-157 studied for Crohn's disease or ulcerative colitis?
In rat models, yes. Both TNBS-induced colitis (a model for Crohn's-like inflammation) and DSS-induced colitis (a model for UC-like inflammation) showed improvement with BPC-157 treatment in animal studies. However, no human trials in Crohn's disease or ulcerative colitis have been completed. Anecdotal reports from IBD patients using BPC-157 exist in online communities, but these are not controlled data.
For gut healing, should I take BPC-157 orally or inject it?
For conditions localized to the GI tract — gastric ulcers, esophagitis, intestinal inflammation — oral administration has mechanistic advantages: the peptide contacts the affected mucosa directly. Rat studies show effective oral dosing. For systemic effects, or if the condition is in the colon (where transit time means the peptide has passed through the upper GI), subcutaneous injection may provide better systemic delivery. There is no human comparative data between routes for GI applications.